ASH Conference News on T315i mutation

[Guest guest]

This was brought up at the ASH convention on December 7, 2009 (New Orleans,

Louisiana) — It has been around for a while, but not that widely used. Now that

Australia has gotten their patent on Omapro, they have found that it has the

potential to treat CML in a unique way, and sometimes alone. Omapro works

independtly of other drugs. I took it in a combo 10 years ago, while Jackie

took it alone for some time and I am thinking it was about 2 years. She was

able to return home and go back to working as a teacher's aid and taking college

courses to become a teacher herself. Wow, that takes courage.

While not in its infancy, it will still take time and trials to see how far they

can go with this. Myelodysplastic syndromes are sometimes the forerunners of

CML, so they are using it for that, too, in hopes of cutting it off at the knees

before it progresses further. It is now used as an orphan drug, as approved by

the FDA. We see more about CML therapies and research than we do the other

blood diseases that are closely related. This is one more bullet for their

rather small arsenal. This is from my paraphrasing and own experience with it,

but if you want to read further, here is the website and there is also a webcam

of Dr. Cortes, which I have not yet listened to:

http://www.medscape.com/viewarticle/713468

FYI,

Lottie Duthu